SynthesisPloS one2020

Eye, hepatobiliary, and renal disorders of erlotinib in patients with non-small-cell lung cancer: A meta-analysis.

Hye Duck Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.